## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.1% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 89 overbought. Stock is in no-man's land without clear edge. Caution: declining volume (39% of avg), momentum weakening (-2.8% MRS), overbought RSI (89).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($98.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-28 | Stifel | $105 | $80 | +31% |
| 2025-11-25 | Canaccord Genui | $105 | $85 | +24% |
| 2025-11-24 | Benchmark | $0 | $0 | 0% |
| 2025-11-24 | Jefferies | $105 | $90 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-28 | Stifel | down | Hold |
| 2025-11-25 | Canaccord Genui | down | Hold |
| 2025-11-24 | Benchmark | down | Hold |
| 2025-11-24 | Jefferies | down | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.8% 5d) with bearish MACD, trend may be turning.
2. Overbought RSI (89) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 5 raises (avg +26%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 90.9x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Analyst sentiment positive (5 raises, avg +26%). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.42 |
| 52W Range | $38.81 - $101.95 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 90.9 |
| Current P/E | 300.5 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 5.9% to 3.1% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.9pp (needs >4.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.20), momentum weakening. RSI overbought at 89, risk of mean reversion. Volume at 39% of 20MA suggests lack of conviction. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.14% (CS: 59) | Neutral |
| RSI_14 | 88.7 | Overbought |
| MACD Histogram | -1.20 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.290x | Above |
| vs SMA200 | 1.777x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.61
- **Stop Loss:** $98.73 (2.8% risk)
- **Target:** $104.49 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 375
- **Position Value:** $38,103.75
- **Portfolio %:** 38.10%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*